Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer
María A. Rodríguez-Hernández,
P de la Cruz-Ojeda,
Mª José López-Grueso,
Elena Navarro-Villarán,
Raquel Requejo-Aguilar,
Beatriz Castejón-Vega,
María Negrete,
Paloma Gallego,
Álvaro Vega-Ochoa,
Victor M. Victor,
Mario D. Cordero,
José A. Del Campo,
J. Antonio Bárcena,
C. Alicia Padilla,
Jordi Muntané
Affiliations
María A. Rodríguez-Hernández
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain; Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
P de la Cruz-Ojeda
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain
Mª José López-Grueso
Department of Biochemistry and Molecular Biology, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
Elena Navarro-Villarán
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain; Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
Raquel Requejo-Aguilar
Department of Biochemistry and Molecular Biology, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
Beatriz Castejón-Vega
Research Laboratory, Oral Medicine Department, University of Seville, Seville, Spain
María Negrete
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain
Paloma Gallego
Unit for the Clinical Management of Digestive Diseases, Hospital University “Nuestra Señora de Valme”, Sevilla, Spain
Álvaro Vega-Ochoa
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain
Victor M. Victor
Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Service of Endocrinology and Nutrition, Hospital University “Doctor Peset”, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain; Department of Physiology, University of Valencia, Valencia, Spain
Mario D. Cordero
Research Laboratory, Oral Medicine Department, University of Seville, Seville, Spain; Department of Physiology, Institute of Nutrition and Food Technology ''José Mataix'', Biomedical Research Center (CIBM), University of Granada, Armilla, Spain
José A. Del Campo
Unit for the Clinical Management of Digestive Diseases, Hospital University “Nuestra Señora de Valme”, Sevilla, Spain
J. Antonio Bárcena
Department of Biochemistry and Molecular Biology, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
C. Alicia Padilla
Department of Biochemistry and Molecular Biology, University of Cordoba, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain
Jordi Muntané
Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain; Centro de Investigación Biomédica en red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain; Department of General Surgery, Hospital University “Virgen del Rocío”/IBiS/CSIC/University of Seville, Seville, Spain; Corresponding author. Institute of Biomedicine of Seville (IBiS), IBiS/Hospital University “Virgen del Rocío”/CSIC/University of Seville, Seville, Spain.
Cancer cells have unlimited replicative potential, insensitivity to growth-inhibitory signals, evasion of apoptosis, cellular stress, and sustained angiogenesis, invasiveness and metastatic potential. Cancer cells adequately adapt cell metabolism and integrate several intracellular and redox signaling to promote cell survival in an inflammatory and hypoxic microenvironment in order to maintain/expand tumor phenotype. The administration of tyrosine kinase inhibitor (TKI) constitutes the recommended therapeutic strategy in different malignancies at advanced stages.There are important interrelationships between cell stress, redox status, mitochondrial function, metabolism and cellular signaling pathways leading to cell survival/death. The induction of apoptosis and cell cycle arrest widely related to the antitumoral properties of TKIs result from tightly controlled events involving different cellular compartments and signaling pathways. The aim of the present review is to update the most relevant studies dealing with the impact of TKI treatment on cell function. The induction of endoplasmic reticulum (ER) stress and Ca2+ disturbances, leading to alteration of mitochondrial function, redox status and phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt)-mammalian target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) signaling pathways that involve cell metabolism reprogramming in cancer cells will be covered. Emphasis will be given to studies that identify key components of the integrated molecular pattern including receptor tyrosine kinase (RTK) downstream signaling, cell death and mitochondria-related events that appear to be involved in the resistance of cancer cells to TKI treatments.